Humana (NYSE:HUM) Stock Rating Lowered by Wall Street Zen

Humana (NYSE:HUM) was downgraded by Wall Street Zen from a “buy” rating to a “hold” rating in a report released on Sunday, Wall Street Zen reports.

Other analysts have also issued research reports about the stock. TD Cowen boosted their price target on shares of Humana from $350.00 to $370.00 and gave the company a “hold” rating in a research report on Friday, July 31st. Mizuho raised their price objective on shares of Humana from $335.00 to $390.00 and gave the stock an “outperform” rating in a report on Monday, June 8th. Bank of America upgraded shares of Humana from a “neutral” rating to a “buy” rating and set a $500.00 price objective for the company in a research note on Wednesday, July 29th. Deutsche Bank Aktiengesellschaft began coverage on shares of Humana in a report on Thursday, July 30th. They set a “hold” rating on the stock. Finally, Oppenheimer restated an “outperform” rating and set a $405.00 target price on shares of Humana in a research report on Thursday, July 30th. Fifteen investment analysts have rated the stock with a Buy rating, fourteen have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Humana has an average rating of “Hold” and an average target price of $408.61.

Humana Stock Down 2.0%

Shares of NYSE HUM opened at $389.91 on Friday. Humana has a one year low of $163.11 and a one year high of $428.88. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.74 and a quick ratio of 1.74. The business’s fifty day moving average price is $386.37 and its 200-day moving average price is $320.31. The stock has a market capitalization of $46.82 billion, a PE ratio of 36.89, a P/E/G ratio of 2.46 and a beta of 0.74.

Humana (NYSE:HUM) last posted its quarterly earnings results on Wednesday, July 29th. The insurance provider reported $7.61 earnings per share for the quarter, topping the consensus estimate of $7.27 by $0.34. Humana had a return on equity of 11.20% and a net margin of 0.88%.The company had revenue of $40.89 billion during the quarter, compared to the consensus estimate of $40.58 billion. During the same quarter in the prior year, the company earned $6.27 EPS. The firm’s quarterly revenue was up 26.2% compared to the same quarter last year. On average, equities research analysts anticipate that Humana will post 9 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Johnson Financial Group Inc. purchased a new stake in shares of Humana in the second quarter worth $26,000. Trust Co. of Vermont purchased a new position in Humana during the second quarter worth about $28,000. Bogart Wealth LLC increased its stake in Humana by 192.0% in the 2nd quarter. Bogart Wealth LLC now owns 73 shares of the insurance provider’s stock worth $29,000 after acquiring an additional 48 shares during the last quarter. MidFirst Bank bought a new position in Humana in the 2nd quarter worth about $35,000. Finally, Fideuram Asset Management Ireland dac purchased a new stake in shares of Humana in the 4th quarter valued at about $27,000. 92.38% of the stock is owned by institutional investors.

Humana Company Profile

Humana Inc (NYSE:HUM) is a U.S.-based health insurance and health care services company focused primarily on government-sponsored programs. Its offerings include Medicare Advantage plans, Medicare prescription drug plans, Medicaid coverage and specialty insurance products, serving individuals, employers and government organizations.

Through its CenterWell business, Humana also provides senior-focused primary care, pharmacy services and home health care. These operations are designed to support coordinated care for older adults and other members with ongoing health care needs.

Humana was founded in 1961 as a nursing-home company and later expanded into hospital ownership before shifting its focus toward health insurance.